Navigation Links
Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
Date:11/16/2010

the event of a smallpox release.  Chimerix has received significant funding from the National Institutes of Allergy and Infectious Disease to develop CMX001 for smallpox.

Chimerix's second clinical-stage antiviral compound, CMX157, has completed Phase 1 clinical studies.  CMX157 is in development as a potent nucleoside analogue against multi-drug resistant HIV infections.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
8. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
9. New forms of highly efficient, flexible nanogenerator technology
10. Verenium to Present at Jefferies 10th Global Clean Technology Conference
11. Voluntary initiatives, regulation and nanotechnology oversight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology,  today celebrated continued positive ... exVive3D TM Human Liver Tissue.  The product, ... release on November 18, has been recognized as ... for innovation. Most recently, on December ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer ... bioimplants processed from human amniotic membrane, announced today ... Systagenix, whereby Systagenix will co-market EpiFix®. The MiMedx ... amniotic tissue, EpiFix® offers a wide variety of ...
... first Minority Biomedical Entrepreneurship Conference (MBEC), will convene ... platform for minority professionals, entrepreneurs, investors, students and ... ideas. (Logo: http://photos.prnewswire.com/prnh/20120319/DC71722LOGO ) ... of the growing biomedical industry workforce, and a ...
... DIEGO and PHILADELPHIA, March 19, 2012 Toby Odenheim, director ... contract research organization (CRO), is slated to present on ... at the Outsourcing in Clinical Trials, East Coast ... Odenheim will speak at 11 a.m. EDT, Wed., March 28, ...
Cached Biology Technology:MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3Minority Biomedical Entrepreneurship Conference 2Minority Biomedical Entrepreneurship Conference 3Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 2Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 3
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... using a novel technique to better understand mineral growth ... Ridge National Laboratory are improving predictions of mineral reactions ... oil pipes clear to sequestering radium. The mineral ... generally, but also because it is the dominant scale-forming ...
... SUNY Downstate Medical Center,s growth into a major center ... awarded SUNY Downstate a four-year challenge grant of $220,000 ... causes, treatment, and prevention of blinding diseases. Douglas R. ... principal investigator. RPB is the world,s leading voluntary organization ...
... one of the most common neurological diseases, more than 4,000 ... decoded over the next five years in a study led ... and several collaborating institutions. Daniel Lowenstein, MD , ... been attempted for identifying the genetic causes of epilepsy, and ...
Cached Biology News:Metadynamics technique offers insight into mineral growth and dissolution 2SUNY Downstate receives grant from research to prevent blindness 2UCSF shares $25-million grant to find epilepsy genes 2UCSF shares $25-million grant to find epilepsy genes 3
... serum is extensively scrutinized, including ... All horses are of ... worming are controlled and documented ... consistency. Pricing: $12/unit ...
... new primer sets added in Dec 2005 ... hours , Detection from as little ... Specific primers available for hundreds of mammalian ... or end-point RT-PCR , Ideal for ...
jub, ajuba homolog (Xenopus laevis)...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: